Phase 1b/2 study of the combination of BL-8040 with atezolizumab in patients with pancreatic cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Motixafortide (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2017 New trial record
- 26 Sep 2017 According to a BioLineRx media release, this trial is expected to begin by the end of 2017.
- 26 Sep 2017 According to a BioLineRx media release, this study is under BioLineRx's cancer immunotherapy collaboration with Genentech to conduct several Phase 1b/2 studies investigating the combination of BL-8040 with atezolizumab in multiple cancer indications, announced in September 2016.